ArticleWorld journal of gastroenterology2026
High PD-L1 expression as a negative prognostic factor in stage III but not in stage II gastric cancer.
Article in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic value of programmed death ligand-1 (PD-L1) expression in patients with gastric or gastroesophageal junction cancer (G/GEJC) at different stages remains unclear. We hypothesized that high PD-L1 expression is associated with poor survival in patients with pathological stage III (pIII) G/GEJC.
aimTo investigate the relation between PD-L1 expression and survival outcomes in patients with pathological stage II (pII)-pIII G/GEJC.
methodsIn this retrospective cohort study, we collected the clinicopathological data of 388 consecutive patients with pII/pIII G/GEJC who underwent gastrectomy without neoadjuvant therapy at Nanfang Hospital, Southern Medical University. Postoperative tissue samples were collected to evaluate PD-L1 expression. Combined positive score (CPS) ≥ 1 was defined as PD-L1-positive, and CPS ≥ 5 as high PD-L1 expression. Survival outcomes were analyzed using Kaplan-Meier and Cox proportional hazards models.
resultsIn pII G/GEJC, no significant differences were found in 3-year disease-free survival (DFS; 88.5%
conclusionHigh PD-L1 expression serves as an independent adverse prognostic biomarker in stage III but not stage II G/GEJC. These findings indicate a stage-dependent prognostic value of PD-L1 expression in G/GEJC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.